PMID- 32737931
OWN - NLM
STAT- MEDLINE
DCOM- 20210901
LR  - 20210901
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 45
IP  - 6
DP  - 2020 Dec
TI  - Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in 
      recurrent cervical cancer patients with poor performance status: A case series.
PG  - 1501-1504
LID - 10.1111/jcpt.13241 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: A large proportion of recurrent cervical cancer 
      (RCC) patients present with poor performance status (PS) after comprehensive 
      treatments, which usually prevents them from opting for clinical trials. We 
      retrospectively analysed the effect and safety of low-dose apatinib and 
      tegafur-gimeracil-oteracil (TGO) in the treatment of these patients. CASE 
      SUMMARY: Six patients treated with low-dose apatinib and TGO showed a disease 
      control rate of 83.3% and grade 1-2 adverse events (AEs). WHAT IS NEW AND 
      CONCLUSION: This case series indicates that low-dose apatinib and TGO could be 
      considered as palliative therapy for RCC patients with poor PS.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Xu, Xiu-Juan
AU  - Xu XJ
AD  - Department of Radiation Oncology, Lianyungang No 2 People's Hospital, 
      Lianyungang, China.
FAU - Wang, Zhong-Ming
AU  - Wang ZM
AD  - Department of Radiation Oncology, Lianyungang No 2 People's Hospital, 
      Lianyungang, China.
FAU - Shang, Yu-Ping
AU  - Shang YP
AD  - Department of Radiation Oncology, Lianyungang No 2 People's Hospital, 
      Lianyungang, China.
FAU - Jiang, Shu-Nian
AU  - Jiang SN
AUID- ORCID: 0000-0002-3544-7094
AD  - Department of Radiation Oncology, Lianyungang No 2 People's Hospital, 
      Lianyungang, China.
LA  - eng
PT  - Case Reports
DEP - 20200801
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - 0 (Drug Combinations)
RN  - 0 (Pyridines)
RN  - 0 (tegafur-gimeracil-oteracil)
RN  - 1548R74NSZ (Tegafur)
RN  - 5S371K6132 (apatinib)
RN  - 5VT6420TIG (Oxonic Acid)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse 
      effects
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Oxonic Acid/administration & dosage
MH  - Palliative Care/*methods
MH  - Pyridines/administration & dosage
MH  - Retrospective Studies
MH  - Tegafur/administration & dosage
MH  - Uterine Cervical Neoplasms/*drug therapy/pathology
OTO - NOTNLM
OT  - apatinib
OT  - cervical cancer
OT  - performance status
OT  - recurrence
OT  - tegafur-gimeracil-oteracil
EDAT- 2020/08/02 06:00
MHDA- 2021/09/02 06:00
CRDT- 2020/08/02 06:00
PHST- 2020/03/25 00:00 [received]
PHST- 2020/06/28 00:00 [revised]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/08/02 06:00 [pubmed]
PHST- 2021/09/02 06:00 [medline]
PHST- 2020/08/02 06:00 [entrez]
AID - 10.1111/jcpt.13241 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2020 Dec;45(6):1501-1504. doi: 10.1111/jcpt.13241. Epub 2020 
      Aug 1.